Home > Boards > US OTC > Biotechs >

Taxus Cardium Pharmaceuticals Group Inc. (CRXM)

CRXM RSS Feed
Add CRXM Price Alert      Hide Sticky   Hide Intro
Moderator: i_like_bb_stock, docj
Search This Board: 
Last Post: 3/3/2021 7:45:48 PM - Followers: 110 - Board type: Free - Posts Today: 0

Investment by Nostrum Pharmaceuticals LLC: https://www.otcmarkets.com/filing/html?id=14182106&guid=TmVFUWUD04P0tth

CRXM accounting firm is top notch: https://www.marcumllp.com/offices

Clinicaltrials.com update August 2020
https://clinicaltrials.gov/ct2/show/NCT02928094?term=generx&rank=1
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
Estimated Study Start Date : January 1, 2020
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : June 1, 2022


Understanding refractory angina and the AFFIRM study:
https://www.myrefractoryangina.com/




Taxus Cardium Announces Name Change To Gene Biotherapeutics

January 10, 2018PR-M01-18-NI-021

 

SAN DIEGO, Jan. 8, 2018 /PRNewswire/— Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc. 

The name change reflects the Company's plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs.  Gene Biotherapeutics is actively pursuing the acquisition of clinical development and commercialization rights to new and innovative, late-stage, DNA-based product opportunities focused on multiple forms of cancer to leverage the company's established and validated adenovector-based technology platform and deep experience in the clinical advancement and commercialization of gene therapy product candidates.

Previously, the Company established Angionetics Inc., an 85% majority-owned subsidiary, to lead Gene Biotherapeutics' cardiovascular clinical research and commercialization activities.  Angionetics is currently focused on independent financings to support advancement of the FDA-cleared, Generx AFFIRM Phase 3 clinical study of patients with refractory angina (myocardial ischemia) due to advanced coronary artery disease. There are an estimated 1.0 million patients with refractory angina in the United States. Gene Biotherapeutics' plan to advance forward to establish Angionetics as an independent company remains unchanged.  As previously reported, Gene Biotherapeutics expects to retain a substantial long-term equity investment in Angionetics following completion of the planned external financings. For more information about the Generx AFFIRM Phase 3 clinical study visit www.MyRefractoryAngina.com.

Angionetics is also considering the initiation of multiple Phase 2 clinical studies to evaluate the Generx angiogenic gene therapy product candidate as a treatment for patients with Cardiac Syndrome X (microvascular dysfunction) and certain forms of congestive heart failure, including ischemic cardiomyopathy.

Angionetics' Generx [Ad5FGF-4] is a first in class, disease altering, one-time administered, late-stage, angiogenic gene therapy product candidate which has been biologically engineered to enhance blood flow (perfusion) in ischemic regions of the heart by leveraging cardiac plasticity to promote the natural formation and growth of microvascular coronary structures (collateral vessels). This is achieved by stimulating and augmenting the heart's innate natural capacity to modulate the enlargement of pre-existing collateral arterioles (arteriogenesis), and to form new capillary vessels (angiogenesis) in select ischemic regions downstream from large coronary arteries.

Angionetics is being uniquely positioned to become a leading molecular interventional cardiology company, and is seeking to develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products focused on the biologic modulation of cardiac conductivity, contraction and angiogenic revascularization to address the global unmet medical needs of millions of patients with multiple forms of heart disease. Consistent with Angionetics' business strategy, the company is currently considering the acquisition of several early-stage gene therapy product candidates.  To learn more about Angionetics visit www.angionetics.com.

As previously reported, Gene Biotherapeutics further plans to monetize its FDA-cleared, U.S.-patented, Excellagen, a highly-purified, aseptically-manufactured, fibrillar bovine collagen [2.6%] flowable dermal matrix for the treatment of diabetic neuropathic lower extremity ulcers, pressure and venous ulcers as well as other wound healing applications.  Excellagen has demonstrated its medical utility as a delivery platform for stem cells, and also carries the potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes.   Excellagen® has been designated as a skin substitute (bearing a unique product Q Code), in accordance with the standards established by the U.S. Centers for Medicare and Medicaid Services (CMS). For more information about Excellagen, visit https://www.youtube.com/watch?v=D2GYCYc_8JE.

As of December 31, 2017, approximately 14.3 million shares of Gene Biotherapeutics Common Stock were issued and outstanding, and approximately 4.6 million additional shares of Common Stock have been reserved for future issuance upon the conversion of the Series A Convertible Preferred Stock.

 
CRXM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CRXM News: Statement of Beneficial Ownership (sc 13d) 03/01/2021 04:52:14 PM
CRXM News: Initial Statement of Beneficial Ownership (3) 03/01/2021 04:47:19 PM
CRXM News: Statement of Ownership (sc 13g) 12/22/2020 03:24:25 PM
PostSubject
#2563  Sticky Note Rounded up some DD for all the new HoldEm777 09/03/20 03:11:53 PM
#3361   If this dude bought in now then, imo, BlackSnake1 03/03/21 07:45:48 PM
#3360   Def Walker 03/03/21 07:28:12 PM
#3359   https://www.stockscores.com/chart.asp?TickerSymbol=crxm&TimeRange=1825&Interval= The Night Stalker 03/03/21 06:19:00 PM
#3358   needs filings The Night Stalker 03/03/21 02:00:14 PM
#3357   I haven't been able to find out much WAR_CTR4Hire 03/02/21 12:14:41 PM
#3356   So who is this guy - just some Walker 03/02/21 12:06:51 PM
#3355   Well, that share structure is based on old BlackSnake1 03/01/21 06:47:38 PM
#3354   I had hopes it was coming after seeing WAR_CTR4Hire 03/01/21 05:58:26 PM
#3353   Had hopes over the weekend the volume was esi23 03/01/21 05:53:59 PM
#3352   No kidding - wasn’t the much needed news WAR_CTR4Hire 03/01/21 05:47:37 PM
#3351   He should have donated money so the company esi23 03/01/21 05:38:10 PM
#3350   https://s3.amazonaws.com/sec.irpass.cc/2452/0001493152-21-005117.htm SCHEDULE WAR_CTR4Hire 03/01/21 05:04:12 PM
#3349   Maybe buy some more when less than..02 CRXM??? Eventually this BlackSnake1 03/01/21 01:19:29 PM
#3348   https://www.stockscores.com/chart.asp?TickerSymbol=crxm&TimeRange=1825&Interval= The Night Stalker 02/28/21 09:41:14 PM
#3347   Imo, CRXM should get their biz in order BlackSnake1 02/27/21 04:44:10 PM
#3346   Maybe! No doubt in mind That it won’t JJ24 02/27/21 10:31:38 AM
#3345   They have been getting current with Super K esi23 02/27/21 07:17:11 AM
#3344   read the DD STILL NOT CURRENT 6 month later The Night Stalker 02/26/21 04:01:20 PM
#3343   Not much going on until filings are current. CRXM? BlackSnake1 02/26/21 01:32:53 PM
#3342   Agreed. WAR_CTR4Hire 02/26/21 01:20:30 PM
#3341   There have been a lot of sellers but Walker 02/26/21 01:14:59 PM
#3340   Nice Walker, I like your confidence sir. WAR_CTR4Hire 02/26/21 01:12:07 PM
#3339   Grabbed some today Walker 02/26/21 01:10:00 PM
#3338   Lots of volume and no real movement for CRXM??? BlackSnake1 02/26/21 01:00:29 PM
#3337   Someone keeps buying as if 'THEY KNOW' the WAR_CTR4Hire 02/26/21 10:57:57 AM
#3336   3 huge catalysts Coming! 1 Get current 2 uplist 3 JJ24 02/26/21 10:32:58 AM
#3335   Still doing it!! TheKid5 02/26/21 09:43:12 AM
#3334   https://www.stockscores.com/chart.asp?TickerSymbol=crxm&TimeRange=1825&Interval= The Night Stalker 02/25/21 06:57:57 PM
#3333   https://www.stockscores.com/chart.asp?TickerSymbol=crxm&TimeRange=1825&Interval= The Night Stalker 02/25/21 03:16:52 PM
#3332   do it do it do it!!!! TheKid5 02/25/21 01:36:45 PM
#3331   Volume coming in! Drop those filings! JJ24 02/25/21 12:40:50 PM
#3330   We are hopeful before end of 2021? If BlackSnake1 02/24/21 08:31:33 PM
#3329   Will be a monster run for sure once JJ24 02/24/21 06:17:08 PM
#3328   Someone keeps buying or bidding the fear here WAR_CTR4Hire 02/24/21 02:36:04 PM
#3327   Not very smart of this company to miss BlackSnake1 02/23/21 06:27:25 PM
#3326   SEC has been suspending more tickers. WAR_CTR4Hire 02/23/21 08:12:18 AM
#3325   And yes, I have averaged down since then, BlackSnake1 02/22/21 06:49:37 PM
#3324   Really seems like these people are not very BlackSnake1 02/22/21 06:19:53 PM
#3323   https://www.barchart.com/stocks/quotes/CRXM/technical-chart?plot=CANDLE&volume=t The Night Stalker 02/22/21 05:55:56 PM
#3322   its slow The Night Stalker 02/19/21 04:29:10 PM
#3321   May 22, 2020 the deal with Nostrum took docj 02/19/21 04:28:11 PM
#3320   This ticker has a hell of a time BlackSnake1 02/18/21 12:31:07 PM
#3319   No doubt! This.makes me wonder if they actually BlackSnake1 02/16/21 03:22:51 PM
#3318   CRXM management really performing at a high level docj 02/16/21 02:53:57 PM
#3317   very interesting monthly chart at second glance The Night Stalker 02/14/21 12:43:34 AM
#3316   Still waiting for the Super 10-K. The new docj 02/12/21 06:26:14 AM
#3315   many monthe later and STILL NOT UP TO The Night Stalker 02/11/21 05:50:58 PM
#3314   any new DD that timeframe has long expired The Night Stalker 02/11/21 05:34:44 PM
#3313   yes i_like_bb_stock 02/10/21 05:48:33 PM
#3312   u still here bro The Night Stalker 02/10/21 05:32:05 PM
PostSubject
Consent Preferences